EGFR and head and neck squamous cell carcinoma: These mechanisms could potentially account for the low therapeutic efficacy of EGFR inhibition in SCCHN38 and could provide rationale for the combination of EGFR and WHSC1L1 inhibition in patients with SCCHN and WHSC1L1 overexpression.